▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2210 by analyst upside · 2026-06-27
ABT
Abbott Laboratories
Healthcare · Market Cap $164B · P/E 26.4x
ANALYST PRICE TARGET
+23.8%
implied upside to consensus target
Current Price $94.12
Consensus Target $116.54
Bull Target $135.0
Bear Target $92.0
Analysts Covering 24
ANALYST CONSENSUS — BUY
Strong Buy
5
Buy
13
Hold
6
Sell
0
52-Week Low $81.97
52-Week High $137.49
YTD Return -23.4%
FUNDAMENTALS
Market Cap $164B
P/E Ratio (TTM) 26.4x
Forward P/E 15.5x
EPS (TTM) $3.57
PEG Ratio 1.34
Dividend Yield 2.70%
Revenue (TTM) $45.1B
Profit Margin 13.9%
52-WEEK RANGE
52-Week Low $81.97
52-Week High $137.49
Current Price $94.12
Bear Target $92.0
Bull Target $135.0
● Now $94.12 ● Target $116.54
TRADING DATA
Avg Volume 13.0M
YTD Return -23.4%
Analyst Count 24
Consensus Buy
Upside to Target +23.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Abbott Laboratories (ABT) is currently trading at $94.12 with a Wall Street consensus price target of $116.54, implying potential upside of 23.8% over the next 12 months. 24 analysts currently cover ABT, with a consensus rating of Buy — 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $135.0, while the most cautious has a target of $92.0.

ABT operates in the Healthcare sector with a market capitalisation of $164B. The stock is down 23.4% year-to-date and is currently trading near the lower end of its 52-week range of $81.97 – $137.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GILD +23.2%
Gilead Sciences, Inc.
$159B · P/E 17.4x · Buy
TMO +16.8%
Thermo Fisher Scientific Inc.
$191B · P/E 28.2x · Buy
DHR +23.5%
Danaher Corporation
$139B · P/E 38.0x · Buy
NONOF +22.5%
Novo Nordisk A/S
$192B · P/E 10.2x · Hold
SYK +16.3%
Stryker Corporation
$128B · P/E 36.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ABT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-04-27 38% win rate (8 calls)
Barclays — Reiterated
Overweight → Overweight 2026-04-20 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-04-17 14% win rate (7 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-04-17 14% win rate (7 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-04-17 Building track record
Benchmark — Reiterated
Buy → Buy 2026-04-17 Building track record
Evercore ISI Group — Reiterated
Outperform → Outperform 2026-04-17 Building track record
B of A Securities — Reiterated
Buy → Buy 2026-04-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →